Note: I meant to say that sub-1% factor activity is SEVERE hemophilia. Normal is from 50% to 150%.
Today I talk again about Zogenix because I was wrong about Study 2 being priced in! Congrats to the ZGNX holders. I also talk about the new FDA guidelines on gene therapy for hemophilia and its implications for spark tx ($ONCE).
Follow me @matthewlepoire
*This is not investment or trading advice*